Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

• Published in: Seminars in cancer biology 2018-10, Vol.52 (Pt 2), p.16-25
• Main Authors: Dieci, Maria Vittoria, Radosevic-Robin, Nina, Fineberg, Susan, van den Eynden, Gert, Ternes, Nils, Penault-Llorca, Frederique, Pruneri, Giancarlo, D’Alfonso, Timothy M., Demaria, Sandra, Castaneda, Carlos, Sanchez, Joselyn, Badve, Sunil, Michiels, Stefan, Bossuyt, Veerle, Rojo, Federico, Singh, Baljit, Nielsen, Torsten, Viale, Giuseppe, Kim, Seong-Rim, Hewitt, Stephen, Wienert, Stephan, Loibl, Sybille, Rimm, David, Symmans, Fraser, Denkert, Carsten, Adams, Sylvia, Loi, Sherene, Salgado, Roberto
• Format: Article
• Language: English
• Subjects: Biomarkers, Tumor - immunology; Breast cancer; Breast Neoplasms - immunology; Cancer; Carcinoma in Situ - immunology; Ductal carcinoma in situ; Female; Humans; Life Sciences; Lymphocytes, Tumor-Infiltrating - immunology; Medical Oncology - methods; Neoadjuvant; Neoadjuvant Therapy - methods; Neoplasm, Residual - immunology; Residual cancer burden; Residual disease; Tumor-infiltrating lymphocytes
• ISSN: 1044-579X; 1096-3650
• DOI: 10.1016/j.semcancer.2017.10.003

Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.